Portal de Periódicos da CAPES

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

2005; Elsevier BV; Volume: 18; Issue: 8 Linguagem: Inglês

10.1038/modpathol.3800396

1530-0285

Mattias Berglund, Ulf Thunberg, Rose‐Marie Amini, Majlis Book, Göran Roos, Martin Erlanson, Johan Linderoth, Michael Dictor, Mats Jerkeman, Eva Cavallin‐Ståhl, Christer Sundström, Suzanne Rehn-Eriksson, Carin Backlin, Hans Hagberg, Richard Rosenquist, Gunilla Enblad,

HER2/EGFR in Cancer Research

Diffuse large B-cell lymphoma (DLBCL) has been shown to be comprised of at least two prognostic entities, depending on its resemblance to normal germinal center or activated B cells, using global gene expression profiling. Also, the expression patterns of bcl-6, CD10 and IRF-4 (also known as MUM1) have been suggested as alternative means of identifying the germinal- and nongerminal center (activated B-cell like) groups. In the present study, we evaluated by immunohistochemistry the expression patterns of CD10, bcl-6, IRF-4 and bcl-2 in a large material of 161 DLBCL patients. Using two different approaches, patients with germinal center phenotype displayed a significantly better survival than the nongerminal center group. Positive staining for bcl-6 or CD10 predicted for superior survival, while expression of IRF-4 alone showed no association with prognosis. Furthermore, expression of bcl-2 was associated with worse event-free survival and overall survival. In a multivariate analysis, a high international prognostic index score (3–5), non-GC phenotype and bcl-2 were independent adverse prognostic factors. Here we confirm the prognostic importance of determining the germinal- or nongerminal center phenotype in patients with DLBCL.